Annual CFF
N/A
December 31, 2024
Summary
- SLN annual cash flow from financing activities is not available.
Performance
SLN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFF
N/A
December 1, 2024
Summary
- SLN quarterly cash flow from financing activities is not available.
Performance
SLN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFF
N/A
December 1, 2024
Summary
- SLN TTM cash flow from financing activities is not available.
Performance
SLN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SLN Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | - | - | - |
| 5 y5 years | - | - | - |
SLN Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time |
Silence Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $15.80 M(+1102.3%) | $163.84 M(+0.8%) |
| Jun 2024 | - | $1.31 M(-99.0%) | $162.59 M(-1.6%) |
| Mar 2024 | - | $133.27 M(+890.4%) | $165.30 M(+415.8%) |
| Dec 2023 | $32.05 M(-38.5%) | $13.46 M(-7.5%) | $32.05 M(+41.4%) |
| Sep 2023 | - | $14.55 M(+262.2%) | $22.66 M(-59.7%) |
| Jun 2023 | - | $4.02 M(>+9900.0%) | $56.21 M(+7.7%) |
| Mar 2023 | - | $23.50 K(-99.4%) | $52.18 M(+0.2%) |
| Dec 2022 | $52.10 M(+25.7%) | $4.07 M(-91.5%) | $52.10 M(+8.0%) |
| Sep 2022 | - | $48.09 M(<-9900.0%) | $48.24 M(-9072.6%) |
| Jun 2022 | - | -$8600.00(-86.1%) | -$537.60 K(+64.6%) |
| Mar 2022 | - | -$61.70 K(-128.9%) | -$326.70 K(-100.8%) |
| Dec 2021 | $41.45 M(+97.1%) | $213.20 K(-131.3%) | $41.45 M(+0.5%) |
| Sep 2021 | - | -$680.50 K(-436.4%) | $41.24 M(-1.6%) |
| Jun 2021 | - | $202.30 K(-99.5%) | $41.92 M(+0.5%) |
| Mar 2021 | - | $41.71 M | $41.71 M |
| Dec 2020 | $21.03 M(+204.1%) | - | - |
| Dec 2019 | $6.91 M(+1497.8%) | - | - |
| Dec 2018 | $432.70 K(+566.7%) | - | - |
| Dec 2017 | $64.90 K(-152.1%) | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2016 | -$124.60 K(-100.2%) | - | - |
| Dec 2015 | $58.01 M(+243.7%) | - | - |
| Dec 2014 | $16.88 M(-45.5%) | - | - |
| Dec 2013 | $30.97 M(+87.0%) | - | - |
| Dec 2012 | $16.56 M(+93.3%) | - | - |
| Dec 2011 | $8.57 M(-55.3%) | - | - |
| Dec 2010 | $19.17 M(+344.6%) | - | - |
| Dec 2009 | $4.31 M(>+9900.0%) | - | - |
| Dec 2008 | $4400.00(-100.0%) | - | - |
| Dec 2007 | $10.25 M(+47.6%) | - | - |
| Dec 2006 | $6.95 M(-57.3%) | - | - |
| Dec 2005 | $16.27 M(>+9900.0%) | - | - |
| Dec 2004 | $9600.00(-99.8%) | - | - |
| Dec 2000 | $5.79 M(-55.3%) | - | - |
| Dec 1999 | $12.95 M(+2599.2%) | - | - |
| Dec 1998 | $479.70 K(+4745.5%) | - | - |
| Dec 1997 | $9900.00(-99.9%) | - | - |
| Dec 1996 | $10.74 M(+326.3%) | - | - |
| Dec 1995 | $2.52 M | - | - |
FAQ
- What is the all time high annual CFF for Silence Therapeutics?
- What is the all time high quarterly CFF for Silence Therapeutics?
- What is the all time high TTM CFF for Silence Therapeutics?
What is the all time high annual CFF for Silence Therapeutics?
Silence Therapeutics all-time high annual cash flow from financing activities is $58.01 M
What is the all time high quarterly CFF for Silence Therapeutics?
Silence Therapeutics all-time high quarterly cash flow from financing activities is $133.27 M
What is the all time high TTM CFF for Silence Therapeutics?
Silence Therapeutics all-time high TTM cash flow from financing activities is $165.30 M